Halozyme Therapeutics
Halozyme Therapeutics is a biotechnology company developing and commercializing novel oncology therapies that target the TME. Our lead proprietary program, PEGPH20, has a unique approach to target solid tumors, potentially increasing access of co-administered anticancer therapies to the tumor. PEGPH20 is in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, cholangiocarcinoma and gallbladder cancer.